Table 2.
Comorbidity characteristics of total patient population
| ADL | IFX | SCK | UST | Total | |
|---|---|---|---|---|---|
| Number of patients | 42 (100%) | 52 (100%) | 21 (100%) | 90 (100%) | 205 (100%) |
| Obesity | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1.1%) | 1 (0.5%) |
| Diabetes without complication/comorbidity | 2 (4.8%) | 4 (7.7%) | 0 (0%) | 6 (6.7%) | 12 (5.9%) |
| Diabetes with complication/comorbidity | 0 (0%) | 2 (3.8%) | 1 (4.8%) | 4 (4.4%) | 7 (3.4%) |
| Hypertension | 6 (14.3%) | 11 (21.2%) | 4 (19.0%) | 28 (31.1%) | 49 (23.9%) |
| Hyperlipidemia | 8 (19.0%) | 13 (25.0%) | 5 (23.8%) | 20 (22.2%) | 46 (22.4%) |
| Subsequent/old myocardial infarction | 0(0%) | 1 (1.9%) | 0(0%) | 1 (1.1%) | 2 (1.0%) |
| Heart failure | 2 (4.8%) | 4 (7.7%) | 0 (0%) | 8 (8.9%) | 14 (6.8%) |
ADL Adalimumab, IFX Infliximab, SCK Secukinumab, UST Ustekinumab, DLMOL Disorders of lipoprotein metabolism and other lipidemias